These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33564743)

  • 1. Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF.
    van der Wall SJ; Teutsch C; Dubner SJ; Diener HC; Halperin JL; Ma CS; Rothman KJ; Paquette M; Zint K; França LR; Lu S; Lip GYH; Huisman MV;
    TH Open; 2021 Jan; 5(1):e35-e42. PubMed ID: 33564743
    [No Abstract]   [Full Text] [Related]  

  • 2. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Bartels DB; Lip GY;
    J Am Coll Cardiol; 2017 Feb; 69(7):777-785. PubMed ID: 28209218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Lu S; Bartels DB; Lip GYH;
    Am Heart J; 2018 Apr; 198():55-63. PubMed ID: 29653649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF Phase III registry : Trends in antithrombotic therapy use in China.
    Liu X; Feng G; Marler SV; Huisman MV; Lip GYH; Ma C
    Thromb J; 2023 Aug; 21(1):83. PubMed ID: 37528405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program.
    Beier L; Lu S; França LR; Marler S; Lip GYH; Huisman MV; Teutsch C; Halperin JL; Zint K; Diener HC; Baker L; Ma CS; Paquette M; Bartels DB; Dubner SJ; Lyrer P; Senges J; Rothman KJ
    PLoS One; 2022; 17(10):e0274237. PubMed ID: 36201473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA-AF registry.
    Ma C; Riou França L; Lu S; Diener HC; Dubner SJ; Halperin JL; Li Q; Paquette M; Teutsch C; Huisman MV; Lip GYH; Rothman KJ;
    J Arrhythm; 2020 Jun; 36(3):408-416. PubMed ID: 32528565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and 2-year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA-AF.
    Dubner SJ; Teutsch C; Huisman MV; Diener HC; Halperin J; Rothman KJ; Ma CS; Chuquiure-Valenzuela E; Bergler-Klein J; Zint K; Riou França L; Lu S; Paquette M; Lip GYH
    ESC Heart Fail; 2020 Oct; 7(5):2679-2689. PubMed ID: 32613745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma C; Zint K; Elsaesser A; Bartels DB; Lip GY;
    Am J Med; 2015 Dec; 128(12):1306-13.e1. PubMed ID: 26239094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescription of DOACs in Patients with Atrial Fibrillation at Different Stages of Renal Insufficiency.
    Hahn K; Lamparter M
    Adv Ther; 2023 Oct; 40(10):4264-4281. PubMed ID: 37594666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
    Albert NM
    Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program.
    McIntyre WF; Conen D; Olshansky B; Halperin JL; Hayek E; Huisman MV; Lip GYH; Lu S; Healey JS
    Clin Cardiol; 2018 Jun; 41(6):744-751. PubMed ID: 29546729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation of Stroke and Major Bleeding to Creatinine Clearance in Patients With Atrial Fibrillation (from the Fushimi AF Registry).
    Abe M; Ogawa H; Ishii M; Masunaga N; Esato M; Chun YH; Tsuji H; Wada H; Hasegawa K; Lip GY; Akao M
    Am J Cardiol; 2017 Apr; 119(8):1229-1237. PubMed ID: 28219663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial.
    Apostolakis S; Guo Y; Lane DA; Buller H; Lip GY
    Eur Heart J; 2013 Dec; 34(46):3572-9. PubMed ID: 23966309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world.
    Kozieł M; Teutsch C; Bayer V; Lu S; Gurusamy VK; Halperin JL; Rothman KJ; Diener HC; Ma CS; Huisman MV; Lip GYH;
    J Arrhythm; 2021 Aug; 37(4):990-1006. PubMed ID: 34386125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal Function Estimates and Dosing of Direct Oral Anticoagulants in Stroke Patients with Atrial Fibrillation: An Observational Study.
    Chen YT; Lin HJ
    Acta Neurol Taiwan; 2018 Jun; 27(2)():39-44. PubMed ID: 31304571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.